[Advances treatment of osteoporosis: new molecules, new strategies]. / Avancées thérapeutiques: nouvelles molécules, nouvelles stratégies.

ABSTRACT

Practitioners already have a wide range of effective drugs for the treatment of osteoporosis, but new options are needed to prevent fractures in patients with this chronic and disabling disease. Recent advances in bone cell biology have revealed new specific targets for the treatment of bone loss, based on inhibition of bone resorption by osteoclasts (anti-RANK ligand antibodies and cathepsin K inhibitors) or stimulation of bone formation by osteoblasts (anti-sclerostin antibodies). These future treatments (anti-RANK ligand antibodies should shortly be available) will add osteoporosis to the growing list of disorders amenable to targeted biotherapies.